IDXX IDEXX LABORATORIES INC /DE
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 874716 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.9%
TTM net income YoY15.1%
TTM EPS YoY17.7%
Revenue 3-yr CAGR9.1%
Net income 3-yr CAGR12.8%
Margins
Gross margin62.7%
Operating margin32.3%
Net margin25.4%
FCF margin28.0%
EBITDA margin35.7%
Returns
ROE68.9%
ROA33.3%
ROIC (approx.)61.4%
Asset turnover1.31x
Leverage & solvency
Liabilities / assets49.6%
Debt / equity0.20x
Current ratio1.19x
Interest coverage43.54x
Cash quality & payout
Operating cash flow / net income1.20x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.21B | $1.22B | $1.14B | $1.09B | $1.11B | $1.11B | $998.43M | $954.29M |
| Cost of revenue | $449.94M | $437.50M | $418.08M | $432.46M | $421.88M | $414.73M | $375.05M | $383.63M |
| Gross profit | $764.30M | $779.09M | $722.74M | $658.11M | $683.35M | $694.73M | $623.38M | $570.66M |
| R&D expense | $68.82M | $65.43M | $65.79M | $66.83M | $63.41M | $61.90M | $59.06M | $57.73M |
| SG&A expense | $123.28M | $116.81M | $119.11M | $108.62M | $105.94M | $98.68M | $91.56M | $101.14M |
| Operating income | $402.35M | $425.57M | $362.59M | $315.61M | $354.85M | $373.05M | $316.53M | $261.69M |
| Interest expense | $7.46M | $10.18M | $7.74M | $9.21M | $10.65M | $11.32M | $7.67M | $7.50M |
| Pretax income | $399.32M | $417.22M | $355.44M | $306.98M | $344.77M | $362.35M | $310.08M | $256.39M |
| Income tax | $82.18M | $78.81M | $77.00M | $58.79M | $70.16M | $68.36M | $67.41M | $40.24M |
| Net income | $317.14M | $338.41M | $278.45M | $248.19M | $274.61M | $293.99M | $242.68M | $216.15M |
| EBITDA | $442.91M | $466.62M | $400.27M | $354.33M | $391.47M | $408.82M | $350.60M | $295.39M |
| EPS (basic) | 4.02 | 4.29 | 3.50 | — | 3.43 | 3.66 | 2.98 | — |
| EPS (diluted) | 4.01 | 4.27 | 3.47 | — | 3.40 | 3.63 | 2.96 | — |
| Weighted avg. shares (diluted) | 79.05M | 79.31M | 80.16M | — | 80.67M | 80.99M | 81.92M | — |
| Banking | ||||||||
| Provision for credit losses | $1.57M | $2.33M | $3.94M | $2.45M | $1.62M | $1.47M | $2.89M | $1.79M |
| Balance sheet | ||||||||
| Cash & equivalents | $197.54M | $196.93M | $200.53M | $180.07M | $208.17M | $164.59M | $163.97M | $288.27M |
| Receivables | $615.80M | $627.08M | $603.54M | $552.38M | $566.88M | $560.56M | $527.46M | $473.57M |
| Inventory | $390.87M | $391.58M | $382.40M | $377.76M | $391.56M | $392.58M | $395.99M | $381.88M |
| Current assets | $1.50B | $1.51B | $1.45B | $1.41B | $1.48B | $1.36B | $1.32B | $1.40B |
| PP&E, net | $732.13M | $733.24M | $740.38M | $747.38M | $739.44M | $739.68M | $717.62M | $713.12M |
| Goodwill | $640.51M | $410.95M | $412.10M | $414.00M | $413.65M | $414.49M | $407.49M | $405.10M |
| Intangibles | $117.77M | $98.17M | $104.75M | $109.84M | $114.79M | $103.73M | $107.41M | $111.68M |
| Total assets | $3.71B | $3.44B | $3.39B | $3.35B | $3.39B | $3.33B | $3.21B | $3.29B |
| Current liabilities | $1.26B | $1.29B | $1.30B | $1.15B | $1.25B | $1.22B | $1.14B | $1.07B |
| Short-term debt | $75.00M | $150.00M | $150.00M | $75.00M | $150.00M | $74.99M | $170.93M | $167.79M |
| Long-term debt | $299.88M | $299.87M | $299.85M | $374.84M | $374.82M | $449.81M | $449.80M | $449.79M |
| Total debt | $374.88M | $449.86M | $449.85M | $449.84M | $524.82M | $524.81M | $620.73M | $617.57M |
| Total liabilities | $1.84B | $1.83B | $1.83B | $1.75B | $1.83B | $1.87B | $1.77B | $1.70B |
| Shareholders' equity | $1.87B | $1.61B | $1.56B | $1.61B | $1.56B | $1.46B | $1.45B | $1.60B |
| Net debt | $177.34M | $252.93M | $249.32M | $269.77M | $316.66M | $360.21M | $456.76M | $329.31M |
| Shares outstanding | 78.79M | 78.87M | 79.24M | 79.71M | 80.00M | 80.15M | 80.74M | 81.60M |
| Cash flow statement | ||||||||
| Operating cash flow | $449.72M | $347.16M | $266.25M | $355.76M | $402.34M | $185.74M | $237.96M | $262.02M |
| Capital expenditure | $28.93M | $24.65M | $31.98M | $29.43M | $31.11M | $34.10M | $30.03M | $29.25M |
| Free cash flow | $420.79M | $322.52M | $234.26M | $326.33M | $371.23M | $151.64M | $207.94M | $232.77M |
| Investing cash flow | -$248.10M | -$25.50M | -$33.54M | -$28.13M | -$44.87M | -$33.63M | -$29.61M | -$39.84M |
| Financing cash flow | -$200.85M | -$325.19M | -$211.43M | -$355.70M | -$313.31M | -$165.63M | -$330.32M | -$232.78M |
| Depreciation & amortization | $40.56M | $41.05M | $37.68M | $38.72M | $36.63M | $35.77M | $34.06M | $33.71M |
| Stock-based compensation | $16.20M | $16.10M | $16.34M | $16.11M | $14.40M | $14.90M | $14.62M | $14.26M |
| Share buybacks | $112.17M | $346.80M | $351.04M | $237.77M | $240.19M | $338.11M | $400.89M | $245.99M |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.